Palavras-chave
HBV
Carcinoma
Como Citar
Copyright © | Todos os direitos reservados.
A revista detém os direitos autorais exclusivos de publicação deste artigo nos termos da lei 9610/98.
Reprodução parcial
É livre o uso de partes do texto, figuras e questionário do artigo, sendo obrigatória a citação dos autores e revista.
Reprodução total
É expressamente proibida, devendo ser autorizada pela revista.
Resumo
Objetivo: Esclarecer e aprofundar o papel dos vírus da hepatite B HBV e HCV nos complexos mecanismos da carcinogênese hepática. Esta pesquisa busca responder à seguinte pergunta norteadora: "Qual a prevalência do HBV e HCV no CHC, e quais fatores relacionados a esses vírus influenciam a gênese da neoplasia maligna do fígado?". Métodos: Realizou-se uma revisão integrativa da literatura, buscando artigos de janeiro de 2019 a dezembro de 2023 na base PubMed, usando os descritores "HCV" AND "liver cancer" e "HBV" AND "liver cancer". Onze artigos foram selecionados após rigorosa triagem. Resultados: A infecção crônica por HBV e HCV responde por uma parcela significativa dos casos de CHC (75-80% na China para HBV; 45% globalmente). Os mecanismos incluem integração do DNA viral (HBV), ativação de oncogenes (N-myc, C-myc), desregulação imune (SOCS, RIG-I, TLR3), alterações epigenéticas (MIR-155, DNMT3A) e o papel da proteína HBx. A inflamação crônica e a fibrose hepática são cruciais. Considerações finais: A infecção crônica pelos vírus HBV e C HCV é a principal causa da fisiopatologia do carcinoma hepatocelular (CHC).
Referências
CAI P, et al. [Relationship between hepatitis B virus X protein and hepatic cellular cancer]. Yao Xue Xue Bao = Acta Pharmaceutica Sinica, 2016; 51(2): 165–173.
CASTANEDA D, et al. From hepatitis A to E: A critical review of viral hepatitis. World Journal of Gastroenterology, 2021; 27(16): 1691–1715.
DENG X, et al. Transmission networks of hepatitis C virus among HIV/HCV-coinfected patients in Guangdong, China. Virology Journal, 2022; 19: 117.
FENTON SE, et al. Epidemiology, mutational landscape and staging of hepatocellular carcinoma. Chinese Clinical Oncology, 2021; 10(1): 2–2.
GIOVANNINI C, et al. Notch Signaling Regulation in HCC: From Hepatitis Virus to Non-Coding RNAs. Cells, 2021; 10(3): 521.
HOUGHTON M. Hepatitis C Virus: 30 Years after Its Discovery. Cold Spring Harbor Perspectives in Medicine, 2019; 9(12): a037069.
INCA: Instituto Nacional do Câncer José Alencar Gomes da Silva. O que é câncer? 2023.
JENG KS, et al. The Role of Endoglin in Hepatocellular Carcinoma. International Journal of Molecular Sciences, 2021; 22(6): 3208.
JIANG XY, et al. Long-term follow-up of cumulative incidence of hepatocellular carcinoma in hepatitis B virus patients without antiviral therapy. World Journal of Gastroenterology, 2021; 27(11): 1101–1116.
KUMADA T, et al. Prediction of Hepatocellular Carcinoma by Liver Stiffness Measurements Using Magnetic Resonance Elastography After Eradicating Hepatitis C Virus. Clinical and Translational Gastroenterology, 2021; 12(4): e00337.
LOBO MN, et al. HCV-HIV Chronic Coinfection Prevalence in Amazon Region. Journal of Clinical Medicine, 2022; 11(24): 7284.
MANI SKK, ANDRISANI O. Interferon signaling during Hepatitis B Virus (HBV) infection and HBV-associated hepatocellular carcinoma. Cytokine, 2019; 124: 154518.
MASON WS, et al. Hepatitis B Virus DNA Integration and Clonal Expansion of Hepatocytes in the Chronically Infected Liver. Viruses, 2021; 13(2): 210.
MENG F, et al. Immunotherapy of HBV-related advanced hepatocellular carcinoma with short-term HBV-specific TCR expressed T cells: results of dose escalation, phase I trial. Hepatology International, 2021; 15(6): 1402–1412.
MS: Ministério da Saúde. Vacina que previne hepatite B está disponível no SUS. 2022.
NAGARAJU GP, et al. Epigenetics in hepatocellular carcinoma. Seminars in Cancer Biology, 2022; 86(Pt 3): 622–632.
ODENWALD MA, PAUL S. Viral hepatitis: Past, present, and future. World Journal of Gastroenterology, 2022; 28(14): 1405–1429.
PANDYARAJAN V, et al. Risk Factors and Biomarkers for Chronic Hepatitis B Associated Hepatocellular Carcinoma. International Journal of Molecular Sciences, 2021; 22(2): 479.
POLLICINO T, CAMINITI G. HBV-Integration Studies in the Clinic: Role in the Natural History of Infection. Viruses, 2021; 13(3): 368.
ROCA SUAREZ AA, et al. Nucleic Acid-Induced Signaling in Chronic Viral Liver Disease. Frontiers in Immunology, 2021; 11: 624034.
SALMAN S, et al. HIF inhibitor 32-134D eradicates murine hepatocellular carcinoma in combination with anti-PD1 therapy. The Journal of Clinical Investigation, [s.d.]; 132(9): e156774.
SARTORIUS K, et al. The Epigenetic Modulation of Cancer and Immune Pathways in Hepatitis B Virus-Associated Hepatocellular Carcinoma: The Influence of HBx and miRNA Dysregulation. Frontiers in Immunology, 2021; 12: 661204.
SIDALI S, et al. New concepts in the treatment of hepatocellular carcinoma. United European Gastroenterology Journal, 2022; 10(7): 765–774.
SONG A, et al. Durability of hepatitis B surface antigen seroclearance and subsequent risk for hepatocellular carcinoma: A meta‐ analysis. Journal of Viral Hepatitis, 2021; 28(4): 601–612.
VOGEL A, et al. Hepatocellular carcinoma. Lancet (London, England), 2022; 400(10360): 1345–1362.
XIE J, et al. The role of SOCS proteins in the development of virus- induced hepatocellular carcinoma. Virology Journal, 2021; 18: 74.
ZHANG Y, et al. Roles of APOBEC3 in hepatitis B virus (HBV) infection and hepatocarcinogenesis. Bioengineered, 2021; 12(1): 2074–2086.